Man Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Man Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-108,806	Closed	-$170K	–	2494
2026 Q1	$170K	Buy	+108,806	New	+$158K	﹤0.01%	2317
2019 Q1	–	Sell	-20,500	Closed	-$136K	–	2022
2018 Q4	$136K	Buy	+20,500	New	+$166K	﹤0.01%	1835

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Man Group's LXRX Position: Q2 2026 in Review

Man Group sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 108,806 shares — an estimated $170K sold.

Man Group first reported a position in LXRX in Q4 2018 and held it in 2 quarters. The position peaked at $170K in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Man Group reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Man Group sold 108,806 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $170K.
Man Group first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Man Group's Lexicon Pharmaceuticals position peaked at $170K in Q1 2026.
149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.